NBP NovaBridge Biosciences
USHealthcareAs of 2026-07-08 16:00
Why NBP matters now
NovaBridge Biosciences (NBP) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.93 with -4.46% on the session and $222.5M in market capitalization; recent performance reads 1-month -10.71% and YTD -62.31%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-4.4M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -0.1%.
The latest indexable market news headline is "NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Xu Cong Claire filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
15.43
P/S
0.00
EV/EBITDA
-36.16
DCF Value
$0.11
FCF Yield
-0.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.5%
ROA
-53.4%
ROIC
-94.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-4.4M | $-0.09 |
| FY 2025 | $0.00 | $-6.6M | $-0.16 |
| Q3 2025 | $0.00 | $-6.8M | $-0.16 |
| Q2 2025 | $0.00 | $-5.5M | $-0.07 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.00
Target (Median)
$9.00
Target Range
$9.00 - $9.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.48
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.